Today we at Capital Mind bring you some exclusive articles . This follows our earlier post on Lupin’s Mandideep facility FDA inspection which was brought to notice in the IIFL report. We continued tracking this and what you see now is a 3 part exclusive unwrapping of the observations reported from the US FDA’s inspection of Lupin Pharmaceutical’s facilities. These documents are available only under the Freedom of Information Act. The posts that we now talk about below will be available only to the Capital Mind Premium subscribers. We hope to have done justice by disclosing the observations from the form 483 which had been inaccessible until now (do note that we will not be sharing the complete form 483s with our readers. However, we will share only certain limited sections of the form 483). Here is a brief of what will be spoken of in the forthcoming posts. The detailed posts would involve disclosure of the form 483, breakdown of the observations to a comprehensive level along with our views and understandings.… (Read On…)
[via Capital Mind]
Follow us @investmentheat – lists / @sectorheat